Hikma Pharmaceuticals (OTCMKTS:HKMPF) Shares Gap Up – Here’s Why

Hikma Pharmaceuticals Plc (OTCMKTS:HKMPF)’s stock price gapped up before the market opened on Friday. The stock had previously closed at $21.0620, but opened at $23.00. Hikma Pharmaceuticals shares last traded at $23.00, with a volume of 1,293 shares.

Analysts Set New Price Targets

Several equities research analysts have recently commented on HKMPF shares. Citigroup reissued a “buy” rating on shares of Hikma Pharmaceuticals in a report on Wednesday, August 12th. Barclays upgraded shares of Hikma Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research note on Tuesday, September 8th. One analyst has rated the stock with a Buy rating and one has given a Hold rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy”.

Hikma Pharmaceuticals Stock Performance

The company has a fifty day moving average price of $21.74 and a two-hundred day moving average price of $20.17.

Hikma Pharmaceuticals Company Profile

Hikma Pharmaceuticals plc is a multinational pharmaceutical company that develops, manufactures and markets a broad range of generic, branded and specialty medicines. Its portfolio includes injectable medicines, oral solid-dose products, inhalation products and other treatments used in hospitals, pharmacies and community-care settings.

The company operates through three principal businesses: Injectables, Generics and Branded Medicines. Hikma supplies injectable products to hospitals and healthcare providers, offers generic medicines primarily in the United States, and markets branded and licensed medicines across the Middle East and North Africa.